Literature DB >> 21690324

Clonally related CD8+ T cells responsible for rapid population of both diffuse nasal-associated lymphoid tissue and lung after respiratory virus infection.

Sherri L Surman1, Rajeev Rudraraju, David L Woodland, Pradyot Dash, Paul G Thomas, Julia L Hurwitz.   

Abstract

The immune system has evolved to use sophisticated mechanisms to recruit lymphocytes to sites of pathogen exposure. Trafficking pathways are precise. For example, lymphocytes that are primed by gut pathogens can, in some cases, be imprinted with CCR9 membrane receptors, which can influence migration to the small intestine. Currently, little is known about T cell trafficking to the upper respiratory tract or the relationship between effectors that migrate to the diffuse nasal-associated lymphoid tissue (d-NALT), the lower airways, and the lung. To determine whether a T cell primed by Ag from a respiratory pathogen is imprinted for exclusive trafficking to the upper or lower respiratory tract or whether descendents from that cell have the capacity to migrate to both sites, we inoculated mice by the intranasal route with Sendai virus and conducted single-cell-sequencing analyses of CD8(+) T lymphocytes responsive to a K(b)-restricted immunodominant peptide, FAPGNYPAL (Tet(+)). Cells from the d-NALT, lung airways (bronchoalveolar lavage), lung, and mediastinal lymph node were examined 10 d postinfection to determine TCR usage and clonal relationships. We discovered that 1) Tet(+) cells were heterogeneous but preferentially used TCR elements TRAV6, TRAV16, and TRBD1; 2) both N and C termini of Vα and Vβ TCR junctions frequently encompassed charged residues, perhaps facilitating TCR αβ pairing and interactions with a neutral target peptide; and 3) T cells in the d-NALT were often clonally related to cells in the lower respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690324      PMCID: PMC3131409          DOI: 10.4049/jimmunol.1100125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

Review 1.  Nasal vaccines.

Authors:  S S Davis
Journal:  Adv Drug Deliv Rev       Date:  2001-09-23       Impact factor: 15.470

2.  Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections.

Authors:  R J Hogan; E J Usherwood; W Zhong; A A Roberts; R W Dutton; A G Harmsen; D L Woodland
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

3.  TCR revision generates functional CD4+ T cells.

Authors:  J Scott Hale; Maramawit Wubeshet; Pamela J Fink
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 4.  Differentiation and homing of IgA-secreting cells.

Authors:  J R Mora; U H von Andrian
Journal:  Mucosal Immunol       Date:  2008-01-23       Impact factor: 7.313

5.  Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.

Authors:  R Sealy; B G Jones; S L Surman; J L Hurwitz
Journal:  Vaccine       Date:  2010-08-01       Impact factor: 3.641

Review 6.  Tracking T cells with tetramers: new tales from new tools.

Authors:  Paul Klenerman; Vincenzo Cerundolo; P Rod Dunbar
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

7.  RAG-dependent peripheral T cell receptor diversification in CD8+ T lymphocytes.

Authors:  Pau Serra; Abdelaziz Amrani; Bingye Han; Jun Yamanouchi; Shari J Thiessen; Pere Santamaria
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

8.  Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut.

Authors:  Rajeev Rudraraju; Sherri Surman; Bart Jones; Robert Sealy; David L Woodland; Julia L Hurwitz
Journal:  Virology       Date:  2011-01-11       Impact factor: 3.616

9.  Paired analysis of TCRα and TCRβ chains at the single-cell level in mice.

Authors:  Pradyot Dash; Jennifer L McClaren; Thomas H Oguin; William Rothwell; Brandon Todd; Melissa Y Morris; Jared Becksfort; Cory Reynolds; Scott A Brown; Peter C Doherty; Paul G Thomas
Journal:  J Clin Invest       Date:  2010-12-06       Impact factor: 14.808

10.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

View more
  5 in total

1.  Reduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient mice.

Authors:  Rajeev Rudraraju; Sherri L Surman; Bart G Jones; Robert Sealy; David L Woodland; Julia L Hurwitz
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

2.  Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

Authors:  Bart G Jones; Robert E Sealy; Rajeev Rudraraju; Vicki L Traina-Dorge; Brad Finneyfrock; Anthony Cook; Toru Takimoto; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2011-11-23       Impact factor: 3.641

3.  Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage.

Authors:  Adam K A Wright; Daniela M Ferreira; Jenna F Gritzfeld; Angela D Wright; Kathryn Armitage; Kondwani C Jambo; Emily Bate; Sherouk El Batrawy; Andrea Collins; Stephen B Gordon
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

4.  Developmental Regulation of Effector and Resident Memory T Cell Generation during Pediatric Viral Respiratory Tract Infection.

Authors:  Thomas J Connors; J Scott Baird; Margot C Yopes; Kyra D Zens; Kalpana Pethe; Thyyar M Ravindranath; Siu-Hong Ho; Donna L Farber
Journal:  J Immunol       Date:  2018-05-30       Impact factor: 5.426

5.  Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.

Authors:  Rafaella O Tostes; Tasson C Rodrigues; Josefa B da Silva; Alessandra S Schanoski; Maria Leonor S Oliveira; Eliane N Miyaji
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.